Critically Ill | 2012_PharmacoCRRT-study:Pharmacokinetics of Anti-infectives in Critically Ill Patients in Need of Continuous Renal Replacement Therapy (CRRT)
Critically Ill research study
What is the primary objective of this study?
The main purpose of the study is to examine if changes in pharmacokinetics of important antiinfectives in Critically Ill patients in need of continuous renal replacement therapy (CRRT), causes inadequate concentrations in plasma. The effect of different modus of CRRT: CVVH and CVVHD will be compared, as well as type of filter, filter lifetime etc. Hypothesis: The risk of incorrect dosage of antiinfectives - to low/ to high- is increased in critically ill patients receiving CRRT. Inadequate plasma concentrations of antiinfectives may contribute to increased mortality in this group.
Who is eligible to participate?
Inclusion Criteria: 1. Patients admitted to ICU in need of antiinfectives: 1. in need of CRRT 2. without acute kidney failure 2. requirement for antiinfectives> 72 hrs 3. Age > 18 yrs 4. signed informed consent Exclusion Criteria: 1. Acute or chronic renal failure not in need of CRRT 2. Age < 18 yrs
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Acute Renal Failure
Acute Kidney Injury
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
antiinfectiva: vancomycin80 patients Completed.
antiinfectiva: meropenem80 patients recruiting
antiinfectiva: flukonazol80 patients
antiinfectiva: cefotaxim80 patients
antiinfectiva: benzylpenicilline80 patients
antiinfectiva: tazobactam piperacillin80 patients recruiting
antiinfectiva: cloxacillin80 patients
antiinfectiva: ciprofloxacin80 patients
Start Date: May 2013
Completed Date: January 2018
Primary Outcome: Sub-therapeutic levels of measured antiinfectiva
Secondary Outcome: SOFA-score
Study sponsors, principal investigator, and references
Principal Investigator: Elin Helset, MD PhD
Lead Sponsor: Oslo University Hospital